pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2008-0-1-101-107pulmo-1758Research ArticleОБЗОРЫREVIEWПрименение антагонистов лейкотриеновых рецепторов при лечении больных бронхиальной астмойAntagonists of leukotriene receptors in treatment of patients with bronchial asthmaЛещенкоИ. В.LeshchenkoI. V.
г. Екатеринбург
ПономареваН. Д.PonomarevaN. D.
г. Екатеринбург
ГОУ ВПО "Уральская государственная медицинская академия Росздрава"Russian FederationОбластная клиническая больница № 1Russian Federation20082802200801101107Copyright © Лещенко И.В., Пономарева Н.Д., 20082008Лещенко И.В., Пономарева Н.Д.Leshchenko I.V., Ponomareva N.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/1758
.
.
ReferencesГлобальная стратегия лечения и профилактики бронхиальной астмы М.: Атмосфера; 2002.Глобальная стратегия лечения и профилактики бронхиальной астмы М.: Атмосфера; 2002.Global strategy for asthma diagnosis and management. The updated 2006 repot is available on www.ginasthma.org.Global strategy for asthma diagnosis and management. The updated 2006 repot is available on www.ginasthma.org.Rabe K.F., Pizzichini E., Stallberg B. Single inhaler therapy with budesonide / formoterol provides superior asthma control compared with fixed dosing with budesonide plus terbutaline as needed. J. Allergy Clin. Immunol. 2004; 113: 116.Rabe K.F., Pizzichini E., Stallberg B. Single inhaler therapy with budesonide / formoterol provides superior asthma control compared with fixed dosing with budesonide plus terbutaline as needed. J. Allergy Clin. Immunol. 2004; 113: 116.Lane S.J. Leucotriene antagonists in asthma and rhinitis. Respir. Med. 1998; 92: 795–809.Lane S.J. Leucotriene antagonists in asthma and rhinitis. Respir. Med. 1998; 92: 795–809.Malmstrom K., Rodriguez)Gomez G., Guerra J. et al. Oral Montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/ Beclomethasone Study Group. Ann. Intern. Med. 1999; 130: 487–495.Malmstrom K., Rodriguez)Gomez G., Guerra J. et al. Oral Montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/ Beclomethasone Study Group. Ann. Intern. Med. 1999; 130: 487–495.Чучалин А.Г. (ред.). Качество жизни у больных бронхиальной астмой и хронической обструктивной болезнью легких. М.: Атмосфера; 2004.Чучалин А.Г. (ред.). Качество жизни у больных бронхиальной астмой и хронической обструктивной болезнью легких. М.: Атмосфера; 2004.Van Staa T.P., Cooper C., Leufkens H.G. The use of inhaled corticosteroids in the United Kingdom and the Netherlands. Respir. Med. 2003; 97 (5): 578–585.Van Staa T.P., Cooper C., Leufkens H.G. The use of inhaled corticosteroids in the United Kingdom and the Netherlands. Respir. Med. 2003; 97 (5): 578–585.Van der Palen J. Klein J.J., Rovers M.M. Compliance with inhaled medication and self-treatment guidelines following self-management programme in adult asthmatics. Eur. Respir J. 1997; 10: 652–657.Van der Palen J. Klein J.J., Rovers M.M. Compliance with inhaled medication and self-treatment guidelines following self-management programme in adult asthmatics. Eur. Respir J. 1997; 10: 652–657.Jones P.W. Testing health status ("quality of life") questionnaires for asthma and COPD. Eur. Respir. J. 1998; 11(1): 5–6.Jones P.W. Testing health status ("quality of life") questionnaires for asthma and COPD. Eur. Respir. J. 1998; 11(1): 5–6.Sawyer S.M., Fardy H.J. Bridging the gap between doctors' and patients' expectations of asthma management. J. Asthma 2003; 40 (2): 131–138.Sawyer S.M., Fardy H.J. Bridging the gap between doctors' and patients' expectations of asthma management. J. Asthma 2003; 40 (2): 131–138.Holgate S.T. What is the place of leukotriene receptor antagonist in clinical practice? Eur. Respir. Rev. 2001; 11 (79): 41–46.Holgate S.T. What is the place of leukotriene receptor antagonist in clinical practice? Eur. Respir. Rev. 2001; 11 (79): 41–46.Buist A.S. Development of evidence based guidelines for inhaled therapeutic interventions in asthma. Eur. Respir. Rev. 1998; 58: 322–323.Buist A.S. Development of evidence based guidelines for inhaled therapeutic interventions in asthma. Eur. Respir. Rev. 1998; 58: 322–323.Wenzel S. New approaches to anti-inflammatory therapy for asthma. Am. J. Med. 1998; 104 (3): 287–300.Wenzel S. New approaches to anti-inflammatory therapy for asthma. Am. J. Med. 1998; 104 (3): 287–300.Boulet L.P. Perception of the role and potential side effects of inhaled corticosteroids among asthmatic patients. Chest 1998; 113 (3): 587–592.Boulet L.P. Perception of the role and potential side effects of inhaled corticosteroids among asthmatic patients. Chest 1998; 113 (3): 587–592.Finkelstein J.A., Lozano P., Farber H.J. Underuse of controller medications among Medicaid-insured children with asthma. Arch. Pediatr. Adolesc. Med. 2002; 156 (6): 562–567.Finkelstein J.A., Lozano P., Farber H.J. Underuse of controller medications among Medicaid-insured children with asthma. Arch. Pediatr. Adolesc. Med. 2002; 156 (6): 562–567.Белевский А.С. Образовательные программы для больных бронхиальной астмой. Пульмонология 1999; прил.: Бронхиальная астма. Руководство для врачей России (формулярная система): 28–33.Белевский А.С. Образовательные программы для больных бронхиальной астмой. Пульмонология 1999; прил.: Бронхиальная астма. Руководство для врачей России (формулярная система): 28–33.Barnes N.C., Pedersen S., Busse W.W. Efficacy and safety of inhaled corticosteroids. New developments. Am. J. Respir. Crit. Care Med. 1998; 157: 1–53.Barnes N.C., Pedersen S., Busse W.W. Efficacy and safety of inhaled corticosteroids. New developments. Am. J. Respir. Crit. Care Med. 1998; 157: 1–53.Krawiec M.E., Wenzel. S.E. Use of leucotriene antagonists in childhood asthma. Curr. Opin. Pediatr. 1999; 11: 540–547.Krawiec M.E., Wenzel. S.E. Use of leucotriene antagonists in childhood asthma. Curr. Opin. Pediatr. 1999; 11: 540–547.Dixon R.A., Diehl R.E., Opas E. Requirement of a 5-lipoxygenase-activating protein for leukotriene sunthesis. Nature 1990; 343: 282–284.Dixon R.A., Diehl R.E., Opas E. Requirement of a 5-lipoxygenase-activating protein for leukotriene sunthesis. Nature 1990; 343: 282–284.Dahel S.E., Rodger I., Botting J.L., eds. Leucotrienes. New concepts and tagets for therapy. London: William Harvey Press; 1998.Dahel S.E., Rodger I., Botting J.L., eds. Leucotrienes. New concepts and tagets for therapy. London: William Harvey Press; 1998.Smith L.J. Newer asthma therapies. Ann. Intern. Med. 1999; 130: 531–532.Smith L.J. Newer asthma therapies. Ann. Intern. Med. 1999; 130: 531–532.Stevenson D.D., Simon R.A., Mathison D.A., Christiansen S.C. Montelukast is only partially effective in inhibiting aspirin responses in aspirin-sensitive asthmatics. Ann. Allerg. 2000; 85: 477–482.Stevenson D.D., Simon R.A., Mathison D.A., Christiansen S.C. Montelukast is only partially effective in inhibiting aspirin responses in aspirin-sensitive asthmatics. Ann. Allerg. 2000; 85: 477–482.Dahlen B., Nizankowska E., Szczeklik A. et al. Benefits from adding the 5-lipoxygenase inhibitor Zileuton to conventional therapy in aspirin-intolerant asthma. Am. J. Respir. Crit. Care Med. 1998; 4: 1187–1194.Dahlen B., Nizankowska E., Szczeklik A. et al. Benefits from adding the 5-lipoxygenase inhibitor Zileuton to conventional therapy in aspirin-intolerant asthma. Am. J. Respir. Crit. Care Med. 1998; 4: 1187–1194.Barnes N.C., Miller C.J. Effect of Leucotriene receptor antagonist therapy on the risk of asthma exacerbations in patients with mild to moderate asthma: an integrated analysis of Zafirlukast trials. Thorax 2000; 55: 478–483.Barnes N.C., Miller C.J. Effect of Leucotriene receptor antagonist therapy on the risk of asthma exacerbations in patients with mild to moderate asthma: an integrated analysis of Zafirlukast trials. Thorax 2000; 55: 478–483.Drazen J.M., Israel E., O'Byrne P.M. Treatment of asthma with drugs modifying the Leucotriene pathway. N. Engl. J. Med. 1999; 340: 197.Drazen J.M., Israel E., O'Byrne P.M. Treatment of asthma with drugs modifying the Leucotriene pathway. N. Engl. J. Med. 1999; 340: 197.Lipworth B.J. Leucotriene-receptor antagonists. Lancet 1999; 353: 57–62.Lipworth B.J. Leucotriene-receptor antagonists. Lancet 1999; 353: 57–62.Busse W.W., Chervinsky P., Condemi J. et al. Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. J. Allergy. Clin. Immunol. 1998; 101: 457–463.Busse W.W., Chervinsky P., Condemi J. et al. Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. J. Allergy. Clin. Immunol. 1998; 101: 457–463.Lofdahl C.G., Reiss T.F., Leff J. et al. Randomised, placebo controlled trial of effect of Leucotriene receptor antagonist, Montelukast, on tapering inhaled corticosteroids in asthmatic patients. Br. Med. J. 1999; 319: 87–90.Lofdahl C.G., Reiss T.F., Leff J. et al. Randomised, placebo controlled trial of effect of Leucotriene receptor antagonist, Montelukast, on tapering inhaled corticosteroids in asthmatic patients. Br. Med. J. 1999; 319: 87–90.Virhow J.C., Prasse A., Naya I. et al. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am. J. Respir. Crit. Care Med. 2000; 162: 578–585.Virhow J.C., Prasse A., Naya I. et al. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am. J. Respir. Crit. Care Med. 2000; 162: 578–585.Kalyoncu A., Karakaya G., Sahin A. Experience of 10 years with Churg-Strauss syndrome: An accompaniment to or a transition from aspirin-induced asthma? Allergol. Immunopathol. 2002; 29 (5): 185–190.Kalyoncu A., Karakaya G., Sahin A. Experience of 10 years with Churg-Strauss syndrome: An accompaniment to or a transition from aspirin-induced asthma? Allergol. Immunopathol. 2002; 29 (5): 185–190.Wechsler D., Finn D., Gunawardena R. et al. Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest 2000; 117: 708–713.Wechsler D., Finn D., Gunawardena R. et al. Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest 2000; 117: 708–713.Franco J. Pulmonary eosinophilia associated with Montelukast. Thorax 1999; 54 (6): 558–560.Franco J. Pulmonary eosinophilia associated with Montelukast. Thorax 1999; 54 (6): 558–560.Hosker H.S., Tuggey J.M. Montelukast and Churg-Strauss syndrome. Thorax 2001; 56 (3): 244.Hosker H.S., Tuggey J.M. Montelukast and Churg-Strauss syndrome. Thorax 2001; 56 (3): 244.Keogh K.A. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and Leucotriene receptor antagonists. Am. J. Med. 2003; 115 (4): 284–290.Keogh K.A. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and Leucotriene receptor antagonists. Am. J. Med. 2003; 115 (4): 284–290.Fish J.E., Kemp J.P., Lockey R.F. Zafirlukast for symptomatic mild-to-moderate asthma: A 13-week multicenter study. Clin. Ther. 1997; 19: 675–690.Fish J.E., Kemp J.P., Lockey R.F. Zafirlukast for symptomatic mild-to-moderate asthma: A 13-week multicenter study. Clin. Ther. 1997; 19: 675–690.Nathan R.A., Bernstein J.A., Bielory L. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. J. Allergy Clin. Immunol. 1998; 102: 935–942.Nathan R.A., Bernstein J.A., Bielory L. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. J. Allergy Clin. Immunol. 1998; 102: 935–942.Suissa S., Dennis R., Ernst P. Effectiveness of the Leucotriene receptor antagonist Zafirlukast for mild-to-moderate asthma. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 1997; 126: 177–183.Suissa S., Dennis R., Ernst P. Effectiveness of the Leucotriene receptor antagonist Zafirlukast for mild-to-moderate asthma. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 1997; 126: 177–183.Ducharme F. Addition of anti-leukotriene agents to inhaled corticosteroids for chronic asthma. The Cochrane Library 2001; Issue 4.Ducharme F. Addition of anti-leukotriene agents to inhaled corticosteroids for chronic asthma. The Cochrane Library 2001; Issue 4.Ducharme F.M. Inhaled glucocorticoids versus Leucotriene receptor antagonists as single agent asthma treatment: systematic review of current evidence. Br. Med. J. 2003; 326 (7390): 621.Ducharme F.M. Inhaled glucocorticoids versus Leucotriene receptor antagonists as single agent asthma treatment: systematic review of current evidence. Br. Med. J. 2003; 326 (7390): 621.Ducharme F.M., Hicks G.C. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. (Cochrane Review). Cochrane Library 2004; Issue 1.Ducharme F.M., Hicks G.C. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. (Cochrane Review). Cochrane Library 2004; Issue 1.Chervinsky P.S., Friedman B., van Bavel J. et al. Effects of montelukast and beclomethasone on airway function and asthma control. J. Allergy Clin. Immunol. 2002; 110 (6): 847–854.Chervinsky P.S., Friedman B., van Bavel J. et al. Effects of montelukast and beclomethasone on airway function and asthma control. J. Allergy Clin. Immunol. 2002; 110 (6): 847–854.Baumgartner R.A., Martinez G., Edelman J.M. et al. Montelukast Asthma Study Group. Distribution of therapeutic response in asthma control between oral montelukast and inhaled beclomethasone. Eur. Respir. J. 2003; 21 (1): 123–128.Baumgartner R.A., Martinez G., Edelman J.M. et al. Montelukast Asthma Study Group. Distribution of therapeutic response in asthma control between oral montelukast and inhaled beclomethasone. Eur. Respir. J. 2003; 21 (1): 123–128.Riccioni G., Vecchia R.D., D'Orazio N. et al. Comparison of montelukast and budesonide on bronchial reactivity in subjects with mild-moderate persistent asthma. Pulm. Pharmacol. Ther. 2003; 16 (2): 111–114.Riccioni G., Vecchia R.D., D'Orazio N. et al. Comparison of montelukast and budesonide on bronchial reactivity in subjects with mild-moderate persistent asthma. Pulm. Pharmacol. Ther. 2003; 16 (2): 111–114.Vaquerizo M.J. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax 2003; 58(3): 204–210.Vaquerizo M.J. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax 2003; 58(3): 204–210.Israel E., Rubin P., Kemp J.P. The effects of inhibition of 5-lipoxygenase by zileuton in mild to moderate asthma. Ann. Intern. Med. 1993; 119: 1059.Israel E., Rubin P., Kemp J.P. The effects of inhibition of 5-lipoxygenase by zileuton in mild to moderate asthma. Ann. Intern. Med. 1993; 119: 1059.Чучалин А.Г., Астафьева Н.Г., Княжеская Н.П. и др. Диагностика и лечение аспириновой астмы. В кн.: Чучалин А.Г.(ред.). Клинические рекомендации. Бронхиальная астма у взрослых. Атопический дерматит. М.: Атмосфера; 2002. 209–229.Чучалин А.Г., Астафьева Н.Г., Княжеская Н.П. и др. Диагностика и лечение аспириновой астмы. В кн.: Чучалин А.Г.(ред.). Клинические рекомендации. Бронхиальная астма у взрослых. Атопический дерматит. М.: Атмосфера; 2002. 209–229.Price D.B., Hernandez D., Magyar P. et al. Adding Montelukast is at least as efficacious as doubling the Budesonide dose in persistent asthma. Am. J. Respir. Crit. Care Med. 2002; 165 (8): 211–216.Price D.B., Hernandez D., Magyar P. et al. Adding Montelukast is at least as efficacious as doubling the Budesonide dose in persistent asthma. Am. J. Respir. Crit. Care Med. 2002; 165 (8): 211–216.Simons F.E.R., Villa J.R., Lee B.W. et al. Montelukast added to budesonide in children with persistent asthma: a randomized, double-blind, crossover study. J. Pediatr. 2001; 138: 694–698.Simons F.E.R., Villa J.R., Lee B.W. et al. Montelukast added to budesonide in children with persistent asthma: a randomized, double-blind, crossover study. J. Pediatr. 2001; 138: 694–698.Laviolette M., Malmstrom K., Lu S. et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Am. J. Respir. Crit. Care Med. 1999; 160: 1862–1868.Laviolette M., Malmstrom K., Lu S. et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Am. J. Respir. Crit. Care Med. 1999; 160: 1862–1868.Tamaoki J., Kondo M., Sakai N. et al. Leucotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. The Tokyo Joshi-Idai Asthma Research Group. Am. J. Respir. Crit. Care Med. 1997; 155: 1235–1240.Tamaoki J., Kondo M., Sakai N. et al. Leucotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. The Tokyo Joshi-Idai Asthma Research Group. Am. J. Respir. Crit. Care Med. 1997; 155: 1235–1240.Laitinen L.A., Zetterstrom O., Holgate S.T. et al. Effects of Accolate in permitting reduced therapy with inhaled steroids: a multicenter trial in patients with doses of inhaled steroids optimised between 800 and 2 000 mcg per day. Allergy 1995; 50 (suppl. 26): 320.Laitinen L.A., Zetterstrom O., Holgate S.T. et al. Effects of Accolate in permitting reduced therapy with inhaled steroids: a multicenter trial in patients with doses of inhaled steroids optimised between 800 and 2 000 mcg per day. Allergy 1995; 50 (suppl. 26): 320.O'Sullivan S., Akveld M., Burke C.M., Poulter L.W. Am. J. Respir. Crit. Care Med. 2003; 167 (5): 745–750.O'Sullivan S., Akveld M., Burke C.M., Poulter L.W. Am. J. Respir. Crit. Care Med. 2003; 167 (5): 745–750.Ducharme F. Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in patients with asthma: systematic review of current evidence. Br. Med. J. 2002; 324: 1545.Ducharme F. Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in patients with asthma: systematic review of current evidence. Br. Med. J. 2002; 324: 1545.Lipworth B.J., Dempsey O.J., Aziz I. Effects of adding a leukotriene antagonist or a long-acting beta 2-agonist in asthmatic patients with the glycine-16 beta2-adrenoceptor genotype. Am. J. Med. 2001; 109: 114–121.Lipworth B.J., Dempsey O.J., Aziz I. Effects of adding a leukotriene antagonist or a long-acting beta 2-agonist in asthmatic patients with the glycine-16 beta2-adrenoceptor genotype. Am. J. Med. 2001; 109: 114–121.McIvor R.A., Pizzichini E., Turner M.O. Potential masking effects of salmeterol on airway inflammation in asthma. Am. J. Respir. Crit. Care Med. 1998; 158: 924–930.McIvor R.A., Pizzichini E., Turner M.O. Potential masking effects of salmeterol on airway inflammation in asthma. Am. J. Respir. Crit. Care Med. 1998; 158: 924–930.Solans R., Bosch J.A., Selva A. et al. Related Articles, Links Montelukast and Churg-Strauss syndrome. Thorax 2002; 57 (2): 183–185.Solans R., Bosch J.A., Selva A. et al. Related Articles, Links Montelukast and Churg-Strauss syndrome. Thorax 2002; 57 (2): 183–185.Kemp J.P. Related Articles, Links Role of leukotriene receptor antagonists in pediatric asthma. Pediatr. Pulmonol. 2000; 30 (2): 177–182.Kemp J.P. Related Articles, Links Role of leukotriene receptor antagonists in pediatric asthma. Pediatr. Pulmonol. 2000; 30 (2): 177–182.Louis R. Medication of the month. Montelukast (Singulair). Rev. Med. Liege 2001; 56(6): 460–462.Louis R. Medication of the month. Montelukast (Singulair). Rev. Med. Liege 2001; 56(6): 460–462.Ringdal N., Pruzinec R., Weber H.H. et al. Related Articles, Links The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma. International Study Group. Respir Med. 2003; 97 (3): 234–241.Ringdal N., Pruzinec R., Weber H.H. et al. Related Articles, Links The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma. International Study Group. Respir Med. 2003; 97 (3): 234–241.Wilson A.M., Dempsey O.J., Sims E.J., Lipworth B.J. Related evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroid. Chest 2001; 119 (4): 1021–1026.Wilson A.M., Dempsey O.J., Sims E.J., Lipworth B.J. Related evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroid. Chest 2001; 119 (4): 1021–1026.Weber R.W., Hoffman M., Reine D.A., Nelson H.S. Incidence of bronchoconstriction due to aspirin, azo dyes, non-azo dyes and preservatives in a population of perennial asthmatics. J. Allergy Clin. Immunol. 1990; 85: 59.Weber R.W., Hoffman M., Reine D.A., Nelson H.S. Incidence of bronchoconstriction due to aspirin, azo dyes, non-azo dyes and preservatives in a population of perennial asthmatics. J. Allergy Clin. Immunol. 1990; 85: 59.Lane S.J. Leucotriene antagonists in asthma and rhinitis. Respir. Med. 1998; 92: 795–809.Lane S.J. Leucotriene antagonists in asthma and rhinitis. Respir. Med. 1998; 92: 795–809.Mastalerz L., Nizankowska E., Sanak M. et al. Clinical and genetic features underlying the response of patients with bronchial asthma to treatment with a Leucotriene receptor antagonist. Eur. J. Clin. Invest. Relat. Articl. 2002; 32 (12): 949–955.Mastalerz L., Nizankowska E., Sanak M. et al. Clinical and genetic features underlying the response of patients with bronchial asthma to treatment with a Leucotriene receptor antagonist. Eur. J. Clin. Invest. Relat. Articl. 2002; 32 (12): 949–955.Paganin F., Poubeau P., Yvin J.L. The effectiveness of Leucotriene antagonists in the treatment of aspirin-intolerant asthmatic patient. Presse Med. 2003; 14: 978–984.Paganin F., Poubeau P., Yvin J.L. The effectiveness of Leucotriene antagonists in the treatment of aspirin-intolerant asthmatic patient. Presse Med. 2003; 14: 978–984.Mastalerz L., Gawlewicz)Mroczka A., Nizankowska E. et al. Protection against exercise-induced bronchoconstriction by Montelukast in aspirin-sensitive and aspirin-tolerant patients with asthma. Clin. Exp. Allergy 2002; 32 (9): 1360–1365.Mastalerz L., Gawlewicz)Mroczka A., Nizankowska E. et al. Protection against exercise-induced bronchoconstriction by Montelukast in aspirin-sensitive and aspirin-tolerant patients with asthma. Clin. Exp. Allergy 2002; 32 (9): 1360–1365.Stevenson D.D., Simon R.A., Mathison D.A. Montelukast is only partially effective in inhibiting aspirin responses in aspirin-sensitive asthmatics. Ann. Allergy Asthma Immunol. 2000; 85: 477–482.Stevenson D.D., Simon R.A., Mathison D.A. Montelukast is only partially effective in inhibiting aspirin responses in aspirin-sensitive asthmatics. Ann. Allergy Asthma Immunol. 2000; 85: 477–482.Volkman J.A., Pontikes P.J. Leukotriene modifiers to prevent aspirin-provoked respiratory reactions in asthmatics. Ann. Pharmacother. 2002; 36 (9): 1457–1461.Volkman J.A., Pontikes P.J. Leukotriene modifiers to prevent aspirin-provoked respiratory reactions in asthmatics. Ann. Pharmacother. 2002; 36 (9): 1457–1461.Новикова Н.Д., Лещенко И.В. Эффективность монтелукаста при 6-месячной терапии больных бронхиальной астмой. Атмосфера: Пульмонол. и аллергол. 2003; 4: 54–56.Новикова Н.Д., Лещенко И.В. Эффективность монтелукаста при 6-месячной терапии больных бронхиальной астмой. Атмосфера: Пульмонол. и аллергол. 2003; 4: 54–56.Novikova N.D., Leshchenko I.V. Application Моntelukast at patients with a mild persistent bronchial asthma. Pulmonology 2004; suppl.: 777.Novikova N.D., Leshchenko I.V. Application Моntelukast at patients with a mild persistent bronchial asthma. Pulmonology 2004; suppl.: 777.Novikova N.D., Leshchenko I.V. Application Моntelukast at patients with moderate persistent bronchial asthma. Pulmonology 2004; suppl.: 778.Novikova N.D., Leshchenko I.V. Application Моntelukast at patients with moderate persistent bronchial asthma. Pulmonology 2004; suppl.: 778.
The authors declare that there are no conflicts of interest present.